Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9PIK3CAPIK3CBPIK3CD
The experimentally established mechanism targets of Fimepinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 7/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 7/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 7/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 6/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 6/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 5/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 5/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 5/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 5/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 4/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 3/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 2/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fimepinostat SCHEMBL1284705 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29493089 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813120 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813054 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666301 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813122 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813051 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666166 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813474 | 0.97 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813327 | 0.97 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2443 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| WO-2025217056-A2 | VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) RECEPTOR ANTAGONISTS FC FUSIONS AND METHODS OF USE | CAMBIUM ONCOLOGY (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250295668-A1 | METHODS FOR INDUCING COLANIC ACID BIOSYNTHESIS | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618997-A1 | COMPOSITIONS AND METHODS FOR IMPROVED CANCER TREATMENT | The Council of the Queensland Institute of Medical Research (AU) | 2025-09-24 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-120136941-A | Anti-aging composition and application thereof | 鲁贝多生命科学公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2022100659-A1 | COMBINATION THERAPY AND METHODS UTILIZING THE SAME | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2022-05-19 | — | — | WO | claimed |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| WO-2022076517-A1 | SUBJECT-SPECIFIC TREATMENTS FOR VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | claimed |
| WO-2022058405-A2 | HISTONE DEACETYLASE INHIBITORS AND USES THEREOF | IFOM - ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-03-24 | — | — | WO | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| WO-2022020514-A1 | COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-27 | — | — | WO | claimed |